Leukemia
Allogeneic transplant overcame poor prognosis of chronic lymphocytic leukemia
Published in Gene Therapy Weekly, January 19th, 2006
In a recent article published in the journal Clinical Cancer Research, scientists in Spain detailed a study conducted "to evaluate the efficacy of reduced intensity conditioning (RIC) allogeneic transplant in 30 patients with poor-prognosis CLL and/or high-risk molecular/cytogenetic characteristics. Eighty-three percent of patients had active disease at the moment of transplant."
"That is, 14 of the 23 patients analyzed (60%) had unmutated immunoglobulin variable heavy-chain gene [IgV(H)] status; 8 of 25 patients (32%) had 11q-, with 4 of them also...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2006-01-19)
More Articles from Gene Therapy Weekly
- Cardiology
New technique may allow stents deliver gene therapy to patients with heart disease - DNA Research
Human RISC couples microRNA biogenesis and posttranscriptional gene silencing - Genetics & Genomics
A novel genomic DNA expression system utilizes a human artificial chromosome vector - Genetics & Genomics
Aromatase genetic variation may contribute to estrogen-dependent disease - Herpes Simplex Virus
Efficacy of oncolytic HSV-1 vectors are improved by multiple transgenes - Angiology
Beta2 -adrenergic receptor overexpression regulates angiogenesis in response to ischemia - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
